Upload
emely-hullett
View
219
Download
3
Tags:
Embed Size (px)
Citation preview
CC BBEE RR
Whole Blood and Blood Components
Diane K. Hall
Consumer Safety Officer CBER, OBRR, DBA
September 16, 2009
2
CC BBEE RR
Presentation Outline• Submission contents• General Standard Operating Procedures
(SOPs)• Whole Blood and blood components
– Whole Blood and Red Blood Cells (RBCs)– RBC Modifications– Autologous Donations– Plasma– Platelets– Cryoprecipitated AHF
3
CC BBEE RR
General Submission Contents 21 CFR 601.12 *
• Cover Letter• Form FDA 356h• Form FDA 2567 with Labels• Chemistry, Manufacturing and Control Section
(CMC) – Appropriate SOPs– Validations and failure investigations – Quality Control (QC) – Records– Contractors’ names, addresses, registration
numbers/CLIA approved
4
CC BBEE RR
General SOPs• 21 CFR 606.100: Maintain SOPs for all steps
followed in collection, processing, storage and distribution of blood and blood components
• 640.4(h): Whole Blood storage temperatures during transport from collection site to processing site:
– Cooling continuously towards 1-10C, or– Held in an environment maintained at a
temperature range specified for that component in the directions for use for the blood collecting, processing, and storage system
5
CC BBEE RR
General SOPs
• 606.160(b)(5)(iv): Validate shipping containers• 606.65(e): Supplies shall be used in a manner
consistent with manufacturer’s instructions• If applicable, submit SOP for Sterile
Connecting Device procedure **
CC BBEE RR
Whole Blood
7
CC BBEE RR
Whole Blood21 CFR 640.1 - 640.6
• 640.2: General requirements– Manufacturing responsibility– Blood container– Reissue of blood
• 640.3: Suitability of donor • 640.4: Collection of the blood• 640.5: Testing the blood
CC BBEE RR
Red Blood Cells
9
CC BBEE RR
RBCs21 CFR 640.10 - 640.17
• 640.11: General requirements– Storage– Inspection
• 640.12: Suitability of donor• 640.13: Collection of the blood• 640.14: Testing the blood• 640.15: Segments for testing• 640.16: Processing
CC BBEE RR
RBC Modifications
Red Blood Cells Washed
Red Blood Cells Rejuvenated
Red Blood Cells Frozen
Red Blood Cells Deglycerolized
11
CC BBEE RR
Considerations for RBC Modifications: Storage and Dating Period
Approved submissions have typically contained • Red Blood Cells Washed
– Storage: 1-6C– Dating period: 24 hours from start of washing process
• Red Blood Cells Rejuvenated– Storage: 1-6C– Dating period: 24 hours from start of washing process
• Red Blood Cells Frozen Rejuvenated– Storage: <-65C– Dating period: 10 years for RBCs collected and stored in
CPD or CPDA-1 or 3 years for RBCs stored in CPD/
AS-1
12
CC BBEE RR
RBC Modifications: Storage and Dating period
640.17, 610.53(c)• Red Blood Cells Frozen (FRBC)
– Storage: <-65C– Dating period: 10 years, or as specified in the
manufacturer’s instructions
• Red Blood Cells Deglycerolized– Storage: 1-6C– Dating period: 24 hours after removal from <65C storage or
as specified in the directions for use for the blood collection, processing, and storage system approved by FDA
13
CC BBEE RR
RBC Modifications: Product QC
Considerations for Red Blood Cells Washed• Approved submissions typically have
contained– Two months of product QC– 4 units/month– RBC Percent Recovery ***– Residual Total Protein ***– Sterility testing (10 units) ***
14
CC BBEE RR
RBC Modifications: Product QC
• Red Blood Cells Deglycerolized and Red Blood Cells Rejuvenated
– RBC Percent Recovery ***– Determination of free hemoglobin ***– Monitor glycerol removal ***– Sterility testing (10 units) ***
CC BBEE RR
Autologous Donations
16
CC BBEE RR
Autologous Donations
• 640.3(b): Donor qualifications• 610.40(d): Infectious disease testing • 606.100(b)(20): Donor deferral
17
CC BBEE RR
Autologous Donations Labels
21 CFR 606.121(i) and (j)• Information identifying the patient, e.g.
– Name, – Blood Group, – Hospital, – Identification Number
• Date of donation• If applicable, “FOR AUTOLOGOUS USE ONLY”• May use a tie tag attached to the container
18
CC BBEE RR
Autologous DonationsLabels (cont.)
606.121(i)(4)• If donor fails to meet any Whole Blood donor
suitability requirements, “FOR AUTOLOGOUS USE ONLY” label replaces the Blood Group label
610.40(h)(2)(ii)(B): • Components that have reactive infectious
disease screening tests must be labeled with the “BIOHAZARD” legend
19
CC BBEE RR
Autologous DonationsLabels (cont.)
610.40(d)• If there is no cross over allowed and the units
are not shipped anywhere else, then no infectious disease testing is required and the unit can be labeled, “DONOR UNTESTED”
• If facilities cross over autologous units or ship to facilities that allow cross over, then all units must be tested for infectious diseases and labeled according to 606.121(i)
20
CC BBEE RR
Autologous DonationsLabels (cont.)
610.40(d)• If products are shipped to another facility that
does not allow cross over, you must assure that the first donation in each 30-day period is tested.
– Tested units: Label according to 606.121. – Untested units: Label as “DONOR TESTED WITHIN
THE LAST 30 DAYS”
CC BBEE RR
Plasma Components
Fresh Frozen Plasma (FFP)
Plasma Cryoprecipitate Reduced
Plasma Frozen Within 24 Hours After Phlebotomy
22
CC BBEE RR
Plasma21 CFR 640.30 – 640.34
• 640.31: Suitability of donors• 640.32: Collection of source material• 640.33: Testing the blood• 640.34: Processing
23
CC BBEE RR
Plasma Components
• 640.34(b), 640.54(a)(2): Separate plasma from RBCs and place in freezer within 8 hours of phlebotomy or within the timeframe specified in the directions for use for the blood collecting, processing and storage system.
• 610.53(c)– Storage: <-18C– Dating period: 1 year from the collection date of
Whole Blood
CC BBEE RR
Platelet Components
Platelets
Pooled Platelets-5d, Leukocytes Reduced
25
CC BBEE RR
Platelets21 CFR 640.20-640.27
• 640.21: Suitability of donors• 640.22: Collection of source material• 640.23: Testing the blood• 640.24: Processing• 640.25: General requirements
– Storage– Quality control testing– Manufacturing responsibility
26
CC BBEE RR
Platelets
• 640.22(d) : Phlebotomy shall be performed by:– A single uninterrupted venipuncture– With minimal damage to and manipulation of
donor’s tissue
27
CC BBEE RR
Platelets
640.24: Processing• Whole Blood temperatures during transport from collection site to processing site shall be maintained as close as possible to a range between 20-24C
• Separate within 4 hours or within the timeframe specified in the direction for use for the blood collecting, processing, and storage system
28
CC BBEE RR
Platelets
640.25: Storage• 20-24C with continuous gentle agitation, or• 1-6C with no agitation
610.53(c): Dating period• 72 hours from the time of collection, or• 5 days, with approved containers
29
CC BBEE RR
Platelets640.24(c) and (d)• The time and speed of the centrifuge should
demonstrate that the manufactured product:– Is an unclumped product– Is without visible hemolysis– Yields a count of >5.5x1010 platelets per unit (75%
of tested units)
• The volume of original plasma used to resuspend the platelets shall maintain a pH of >6.2
30
CC BBEE RR
Considerations for Platelets:Product QC
• Approved submissions have typically contained two consecutive months of product QC
• 21 CFR 640.25– 4 units/month– pH– Platelet count – Plasma volume
31
CC BBEE RR
Platelets: Product QC
640.24(c), 640.25: Acceptance Criteria forPlatelets• pH: >6.2• Platelet yield: 5.5x1010 platelets/unit in >75% of
tested units
32
CC BBEE RR
Considerations for Pooled Platelets-5d, Leukocytes Reduced
Approved submissions have typically contained• Manufacturing: Use a process based on the
manufacturer’s package insert that is capable of demonstrating the specified acceptance criteria
33
CC BBEE RR
Considerations for Pooled Platelets-5d, Leukocytes Reduced
Approved submissions have typically contained• Product QC
– Two consecutive months of product QC – Statistically sound plan– Ensure products meet specifications stated in the
manufacturer’s instructions• Acceptance Criteria
– Acceptance criteria: manufacturer’s recommendations for product specifications
CC BBEE RR
Cryoprecipitate Components
Cryoprecipitated AHF
Pooled Cyroprecipitated AHF
35
CC BBEE RR
Cryoprecipitated AHF: 21 CFR 640.50 – 640.56
• 640.51: Suitability of donors• 640.52: Collection of source material• 640.53: Testing the blood• 640.54: Processing• 640.56: Quality control test for potency
36
CC BBEE RR
Cryoprecipitated AHF
640.54(a): Processing Plasma (cryo rich)
• Separate plasma by centrifugation• Place plasma in freezer within 8 hours after
collection or within the timeframe specified in the directions for use for the blood collecting, processing, and storage system
• Store plasma at <-18C until further processed
37
CC BBEE RR
Cryoprecipitated AHF
640.54(b): Processing Final Product• Separate the Cryoprecipitated AHF from the
plasma by a procedure that has been shown to produce an average of >80 IU of AHF/final container
• Do not add diluent prior to freezing final product
38
CC BBEE RR
Cryoprecipitated AHF
610.53(c): for Cryoprecipitated AHF• Storage: <-18C• Dating period: 1 year from the date of Whole
Blood collection
39
CC BBEE RR
Considerations for Cryoprecipitated AHF
• Approved submissions typically have contained two consecutive months of product QC
• 21 CFR 606.122(n), 640.56– 4 units/month– Fibrinogen– AHF potency– Acceptance Criteria
• Fibrinogen: >150 mg• Mean AHF potency: >80 IU of AHF/final container
40
CC BBEE RR
Considerations for Pooled Cryoprecipitated AHF
Approved submissions have typically contained• Manufacturing
– Use of Sterile Connecting Device **– Storage: <-18C– Dating period: 1 year from the oldest unit’s date of
collection
• Product QC and Acceptance Criteria– Same as Cryoprecipitated AHF
41
CC BBEE RR
References* Guidance for Industry: Changes to an Approved Application:
Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture
** Guidance for Industry: Use of Sterile Connecting Devices in Blood Bank Practices
***Guidance for Industry For the Submission of Chemistry, Manufacturing and Controls and Establishment Description Information for Human Blood and Blood Components Intended for Transfusion or for Further Manufacture and For the Completion of the Form FDA 356h “Application to Market a New Drug, Biologic or an Antibiotic Drug for Human Use”
http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/default.htm
Eight-Hour Hold
http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/OtherRecommendationsforManufacturers/MemorandumtoBlood
Establishments/default.htm
42
CC BBEE RR
Questions - Contact us!
• Mailing address:
Director, Division of Blood Applications, OBRR, CBER, FDAHFM-370c/o Document Control Center, HFM-991401 Rockville Pike, Suite 200NRockville, MD 20852-1448
• Telephone: 301-827-3543
• FAX: 301-827-3534